Relay Therapeutics (NASDAQ:RLAY) CFO Sells 17,717 Shares of Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.94, for a total transaction of $335,559.98. Following the sale, the chief financial officer owned 122,851 shares of the company’s stock, valued at $2,326,797.94. The trade was a 12.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, July 28th, Thomas Catinazzo sold 1,459 shares of Relay Therapeutics stock. The shares were sold at an average price of $18.61, for a total value of $27,151.99.
• On Monday, July 6th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $18.69, for a total transaction of $331,130.73.
• On Monday, June 22nd, Thomas Catinazzo sold 187,163 shares of Relay Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $3,176,156.11.

Relay Therapeutics Stock Performance

RLAY traded down $0.45 on Wednesday, hitting $18.66. The company had a trading volume of 5,942,384 shares, compared to its average volume of 3,175,174. The stock has a fifty day moving average price of $19.35 and a 200-day moving average price of $15.27. Relay Therapeutics, Inc. has a 12-month low of $3.87 and a 12-month high of $21.27. The stock has a market capitalization of $4.09 billion, a price-to-earnings ratio of -11.89 and a beta of 1.69.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. Analysts forecast that Relay Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group raised their price target on shares of Relay Therapeutics from $22.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. HC Wainwright increased their price objective on shares of Relay Therapeutics from $28.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a report on Monday, July 6th. Wall Street Zen downgraded shares of Relay Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, UBS Group set a $26.00 price target on Relay Therapeutics in a research report on Tuesday, May 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $25.92.

Institutional Investors Weigh In On Relay Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in RLAY. Allworth Financial LP purchased a new position in Relay Therapeutics during the second quarter valued at $34,000. Meeder Asset Management Inc. purchased a new stake in shares of Relay Therapeutics during the second quarter worth about $62,000. KBC Group NV acquired a new position in shares of Relay Therapeutics during the 1st quarter worth about $34,000. Integrated Wealth Concepts LLC acquired a new position in shares of Relay Therapeutics during the 2nd quarter worth about $74,000. Finally, Smartleaf Asset Management LLC lifted its stake in Relay Therapeutics by 288.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,426 shares of the company’s stock valued at $37,000 after buying an additional 3,287 shares in the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.